A recurring theme in the way that many pharmaceutical companies approach new technologies is that they are initially extremely enthusiastic, perhaps excessively so, but then subsequently overreact in the opposite direction, abandoning them when the first bumps in the road come along. Only a few years ago, the affection of big pharma for RNA interference (RNAi) seemed unlimited. Merck had acquired Sirna Therapeutics for .1 billion, and Novartis was collaborating with Alnylam, another leading developer of RNAi-based therapeutics.
No takes yet. Share an insight, caveat, or question.
Arthur Μ. Krieg (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: